<DOC>
	<DOC>NCT02038296</DOC>
	<brief_summary>To evaluate local tumor control and survival rate after repeated transarterial chemoembolization(TACE) using three different protocols in hepatocellular carcinoma (HCC) patients.</brief_summary>
	<brief_title>Different Protocols for Repeated Transarterial Chemoembolization in the Treatment of Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Patients with histologically confirmed HCC with unresectable disease without extrahepatic metastases; HCC with no previous treatment; age between 18 and 75 years; Life expectancy of at least 8 weeks; main tumor size greater than 5 cm; adequate hematologic function (platelet count: &gt;60 × 109 platelets/L; hemoglobin: &gt;90g/L; and prothrombin time: &lt;3 seconds above control); adequate renal function (serum creatinine: ≤1.5 × upper limit of normal); ChildPugh classification A or B grade; Barcelona Clinic Liver Cancer (BCLC) stage B or C; Eastern Cooperative Group performance status of zero or one. a hypovascular tumor (defined as a tumor with all its parts less contrastenhanced than the nontumorous liver parenchyma on arterial phase computed tomography scans); diffusetype HCC; evidence of hepatic decompensation including esophageal or gastric variceal bleeding or hepatic encephalopathy; severe underlying cardiac or renal diseases; color Doppler ultrasonography showing portal vein tumor thrombosis with complete main portal vein obstruction without cavernous transformation; or obstructive jaundice.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Transarterial chemoembolization</keyword>
	<keyword>Gemcitabine</keyword>
</DOC>